Patents by Inventor Sundaramoorthi Swaminathan

Sundaramoorthi Swaminathan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds
    Publication number: 20050209197
    Abstract: Phosphonate substituted compounds with HIV protease inhibitory properties having use as therapeutics and for other industrial purposes are disclosed. The compositions inhibit HIV protease activity and/or are useful therapeutically for the treatment of AIDS and other antiviral infections, as well as in assays for the detection of HIV protease.
    Type: Application
    Filed: April 25, 2003
    Publication date: September 22, 2005
    Inventors: Murty Arimilli, Mark Becker, Clifford Bryant, James Chen, Xiaowu Chen, Azar Dastgah, Maria Fardis, Gong-Xin He, Haolun Jin, Choung Kim, William Lee, Christopher Lee, Kuei-Ying Lin, Hongtao Liu, Richard Mackman, Michael Mitchell, Peter Nelson, Hyung-Jung Pyun, Tanisha Rowe, Mark Sparacino, Sundaramoorthi Swaminathan, James Tario, Jianying Wang, Matthew Williams, Lianhong Xu, Zheng-Yu Yang, Richard Yu, Jiancun Zhang, Lijun Zhang
  • Method and compositions for identifying anti-HIV therapeutic compounds
    Publication number: 20040121316
    Abstract: Methods are provided for identifying anti-HIV therapeutic compounds substituted with carboxyl ester or phosphonate ester groups. Libraries of such compounds are screened optionally using the novel enzyme GS-7340 Ester Hydrolase. Compositions and methods relating to GS-7340 Ester Hydrolase also are provided.
    Type: Application
    Filed: April 25, 2003
    Publication date: June 24, 2004
    Applicant: GILEAD SCIENCES, INC.
    Inventors: Gabriel Birkus, James M. Chen, Xiaowu Chen, Tomas Cihlar, Eugene J. Eisenberg, Marcos Hatada, Gong-Xin He, Choung U. Kim, William A. Lee, Martin J. McDermott, Sundaramoorthi Swaminathan
  • Modified internucleoside linkages (ii)
    Patent number: 6683166
    Abstract: The invention relates to novel modified oligonucleotides, the construction thereof, and their use in oligonucleotide-based therapies. More specifically, the invention is to novel oligonucleotides having modified internucleoside linkages which are resistant to nucleases, having enhanced ability to penetrate cells, and which are capable of binding target oligonucleotide sequences in vitro and in vivo. The modified oligonucleotides of the invention are particularly useful in oligonucleotide-based therapies utilizing the modified oligonucleotides to interrupt protein synthesis or transcription or to otherwise inactivate messenger RNA or double stranded DNA.
    Type: Grant
    Filed: June 21, 2002
    Date of Patent: January 27, 2004
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Sundaramoorthi Swaminathan, Mark Matteucci, Jeff Pudlo, Robert J. Jones
  • Modified internucleoside linkages (ii)
    Publication number: 20030120050
    Abstract: The invention relates to novel modified oligonucleotides, the construction thereof, and their use in oligonucleotide-based therapies. More specifically, the invention is to novel oligonucleotides having modified internucleoside linkages which are resistant to nucleases, having enhanced ability to penetrate cells, and which are capable of binding target oligonucleotide sequences in vitro and in vivo. The modified oligonucleotides of the invention are particularly useful in oligonucleotide-based therapies utilizing the modified oligonucleotides to interrupt protein synthesis or transcription or to otherwise inactivate messenger RNA or double stranded DNA.
    Type: Application
    Filed: June 21, 2002
    Publication date: June 26, 2003
    Inventors: Sundaramoorthi Swaminathan, Mark Matteucci, Jeff Pudlo, Robert J. Jones
  • Modified internucleoside linkages (II)
    Patent number: 6410702
    Abstract: The invention relates to novel modified oligonucleotides, the construction thereof, and their use in oligonucleotide-based therapies. More specifically, the invention is to novel oligonucleotides having modified internucleoside linkages which are resistant to nucleases, having enhanced ability to penetrate cells, and which are capable of binding target oligonucleotide sequences in vitro and in vivo. The modified oligonucleotides of the invention are particularly useful in oligonucleotide-based therapies utilizing the modified oligonucleotides to interrupt protein synthesis or transcription or to otherwise inactivate messenger RNA or double stranded DNA.
    Type: Grant
    Filed: October 2, 1998
    Date of Patent: June 25, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Sundaramoorthi Swaminathan, Mark Matteucci, Jeff Pudlo, Robert J. Jones
  • Polyhydroxy benzoic acid derivatives and their use as neuraminidase inhibitors
    Patent number: 5958973
    Abstract: The present invention is directed to compositions of the formula: ##STR1## wherein: R.sub.2 is H, or an alkyl group having 1 to 3 carbon atoms and 0 to 2 hydroxyls;R.sub.3 is H, or hydroxyl;R.sub.4 is H, or forms a hydrolyzable ester or amide with --CO.sub.2 --;R.sub.5 are H, or are taken together to form .dbd.NH; andR.sub.6 comprises an amine, or a group having 1 to 12 carbon atoms and 1 to 3 amine groups. The invention is also directed to methods of inhibiting the activity of neuraminidase using the compounds of the invention.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: September 28, 1999
    Assignee: Gilead Sciences, Inc.
    Inventors: Norbert W. Bischofberger, Choung U. Kim, Willard Lew, Hongtao Liu, John C. Martin, Sundaramoorthi Swaminathan, Matthew A. Williams
  • Modified internucleoside linkages (II)
    Patent number: 5817781
    Abstract: The invention relates to novel modified oligonucleotides, the construction thereof, and their use in oligonucleotide-based therapies. More specifically, the invention is to novel oligonucleotides having modified internucleoside linkages which are resistant to nucleases, having enhanced ability to penetrate cells, and which are capable of binding target oligonucleotide sequences in vitro and in vivo. The modified oligonucleotides of the invention are particularly useful in oligonucleotide-based therapies utilizing the modified oligonucleotides to interrupt protein synthesis or transcription or to otherwise inactivate messenger RNA or double stranded DNA.
    Type: Grant
    Filed: June 1, 1992
    Date of Patent: October 6, 1998
    Assignee: Gilead Sciences, Inc.
    Inventors: Sundaramoorthi Swaminathan, Mark Matteucci, Jeff Pudlo, Robert J. Jones
  • Nuclease stable and binding competent oligomers and methods for their use
    Patent number: 5792608
    Abstract: Oligomers are disclosed which have modified internucleotide linkages and can form triplex and duplex structures by binding to complementary nucleic acid sequences. The oligomers of the invention may be incorporated into carriers and may be constructed to have any desired sequence. Compositions of the invention can be used for diagnostic purposes in order to detect viruses or disease conditions.
    Type: Grant
    Filed: April 6, 1995
    Date of Patent: August 11, 1998
    Assignee: Gilead Sciences, Inc.
    Inventors: Sundaramoorthi Swaminathan, Mark Matteucci, Robert J. Jones, Jeff Pudlo, John Munger